Aquestive Therapeutics
AQST
49 hedge funds and large institutions have $99.6M invested in Aquestive Therapeutics in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
36% more funds holding
Funds holding: 36 → 49 (+13)
10% more capital invested
Capital invested by funds: $90.5M → $99.6M (+$9.11M)
0.11% more ownership
Funds ownership: 57.62% → 57.72% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.12M |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
+$801K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$680K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$380K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$338K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$2.35M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$916K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$662K |
| 4 |
Millennium Management
New York
|
-$145K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$107K |
AQST Hedge Fund Activity: Q1 2019 in Review
49 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2019, worth a combined $99.6M — up 10% from $90.5M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AQST positions and 6 closed out — a net gain of 13 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $1.12M. The largest seller was AllianceBernstein, cutting an estimated $2.35M.
- 49 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2019, up from 36 in Q4 2018.
- Funds reported $99.6M of Aquestive Therapeutics stock for Q1 2019, up 10% quarter-over-quarter.
- 19 funds opened new Aquestive Therapeutics positions in Q1 2019 and 6 closed out, a net change of +13 holders.
- The largest Aquestive Therapeutics buyer in Q1 2019 was BlackRock, an estimated $1.12M added.
- The largest Aquestive Therapeutics seller in Q1 2019 was AllianceBernstein, an estimated $2.35M sold.
Based on aggregated 13F filings for Q1 2019.